Skip to content

Evaluation of the Magnesium sulfate effect in ischemic stroke treatment

Evaluation of the intravenous Magnesium sulfate effect in clinically improvement of patient with acute ischemic stroke

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT138901101856N2
Enrollment
97
Registered
2010-03-30
Start date
2010-03-11
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ischemic stroke. Stroke

Interventions

Intervention 1: Magnesium sulfate 4gr IV in 50 cc normal saline over 15 minutes followed by 16 gr in 100cc over 24 hours. Intervention 2: equal volumes of normal saline.
Treatment - Drugs
Placebo
Magnesium sulfate 4gr IV in 50 cc normal saline over 15 minutes followed by 16 gr in 100cc over 24 hours
equal volumes of normal saline

Sponsors

Vice-chancellor for research, Kermanshah University of Medical Sciences and Health Services
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 95 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: patient’s age between 40-95 years,last known well time within 12 hoursof treatment initiation . Exclusion criteria:pregnancy-coma -heart block-chronic renal impairment- respiratory distress(24 220mmhg- pre-existing neuralgic psychiatric or advanced systemic disease that confound neuralgical or functional outcome evaluation -hemorrhagic stroke - known recent stroke wheithin past 30 days- rapidly resolving deficit

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Measure of global disability. Timepoint: before of the treatment ,3days after treatment and discharge time. Method of measurement: according to modified Rankin scale.;Mortality rate. Timepoint: During admition times. Method of measurement: patient' s medical documents.;Amount of admition times. Timepoint: discharge time. Method of measurement: patient' s medical documents.

Secondary

MeasureTime frame
Clinical side effects. Timepoint: daily. Method of measurement: According to patients daily notes.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Dariush Afshari

Emam Reza hospital

dafshari@kums.ac.ir+98 83 1427 6309

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026